Tei Index in Fabry Disease - 31/08/11
Reprint requests: Frank Weidemann, MD, Medizinische Klinik und Poliklinik I, Zentrum für Innere Medizin, Oberdürrbacher Straße 6, 97080 Würzburg, Germany.Abstract |
Background |
Systolic and diastolic dysfunction of the left ventricle are present in patients with cardiac involvement in Fabry disease. The aim of this study was to investigate the diagnostic value of the Tei index, a marker for combined diastolic and systolic function, in patients with Fabry disease.
Methods |
A total of 66 consecutive patients with genetically confirmed Fabry disease were included in this study. Standard echocardiography, including the Tei index, and magnetic resonance imaging were performed. Patients were followed for 2.9 ± 1.9 years; 56 patients received enzyme replacement therapy, and 10 patients had natural history follow-up. Patients were subdivided into three groups: (1) those without cardiac involvement, (2) those with left ventricular (LV) hypertrophy and without late enhancement on magnetic resonance imaging, and (3) those with late enhancement on magnetic resonance imaging.
Results |
The Tei index was significantly higher in the groups 2 (0.56 ± 0.10) and 3 (0.60 ± 0.16) compared with patients without cardiac involvement (0.44 ± 0.10) (P < .001). All patients with Tei indexes > 0.64 showed signs of cardiomyopathy. In contrast, ejection fractions were normal in all three patient groups and therefore not useful for the detection of cardiac involvement. A significant positive correlation was observed between LV wall thickness and the Tei index in the complete patient cohort. Moreover, receiver operating characteristic analysis revealed a large area under the curve for Tei index and hypertrophy, while the area under the curve for fibrosis was small. The Tei index remained unchanged in the natural history and enzyme replacement therapy groups during follow-up.
Conclusions |
In this cohort, the Tei index was of limited value to detect myocardial fibrosis and monitor enzyme replacement therapy. However, the progression of cardiomyopathy toward LV hypertrophy seems to be paralleled by global functional impairment, which can be assessed by the Tei index but not by ejection fraction. Thus, the Tei index seems to be a global parameter that can detect LV functional reduction in patients with Fabry disease.
Le texte complet de cet article est disponible en PDF.Keywords : Tei index, Cardiomyopathy, Fabry disease
Abbreviations : EF, ERT, FD, LE, LV, MRI
Plan
| Dr. Wanner is a member of the European Advisory Board of the Fabry Registry, sponsored by Genzyme Corporation (Cambridge, MA), and has received travel assistance, speaking fees, and research support. Drs. Niemann, Weidemann, and Breunig have received speaking fees from Genzyme Corporation. |
Vol 24 - N° 9
P. 1026-1032 - septembre 2011 Retour au numéro
Article précédent
- Tissue Doppler Imaging and Plasma BNP Levels to Assess the Prognosis in Patients with Hypertrophic Cardiomyopathy
- Hiroaki Kitaoka, Toru Kubo, Makoto Okawa, Nana Takenaka, Chiyo Sakamoto, Yuichi Baba, Kayo Hayashi, Naohito Yamasaki, Yoshihisa Matsumura, Yoshinori L. Doi
- Myocardial Strain Assessment in Cystic Fibrosis
- Fabien Labombarda, Arnaud Pellissier, Madiha Ellafi, C. Creveuil, Virginie Ribault, Murielle Laurans, Marcel Guillot, Emmanuel Bergot, Gilles Grollier, Paul Milliez, Gérard Zalcman, Eric Saloux
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?